{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:17:51Z","timestamp":1794856671598,"version":"4.9.1"},"reference-count":28,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0383-1","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T10:33:21Z","timestamp":1531737201000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":433,"title":["Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab"],"prefix":"10.1136","volume":"6","author":[{"given":"Mariaelena","family":"Capone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Mallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Festino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Maria","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Vanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Paone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesta","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"383_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"383_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u201361.","journal-title":"Cancer Cell"},{"key":"383_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol"},{"key":"383_CR4","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"383_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"383_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"383_CR7","doi-asserted-by":"publisher","first-page":"e493","DOI":"10.1016\/S1470-2045(14)70263-3","volume":"15","author":"CI Diakos","year":"2014","unstructured":"Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer- related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493\u2013503.","journal-title":"Lancet Oncol"},{"key":"383_CR8","first-page":"5","volume":"102","author":"R Zahorec","year":"2001","unstructured":"Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102:5\u201314.","journal-title":"Bratisl Lek Listy"},{"key":"383_CR9","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/sj.bjc.6604027","volume":"97","author":"EF Leitch","year":"2007","unstructured":"Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266\u201370.","journal-title":"Br J Cancer"},{"key":"383_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.lungcan.2014.06.015","volume":"85","author":"S Kumagai","year":"2014","unstructured":"Kumagai S, Marumo S, Shoji T, Sakuramoto M, Hirai T, Nishimura T, et al. Prognostic impact of preoperative monocyte counts in patients with resected lung adenocarcinoma. Lung Cancer. 2014;85:457\u201364.","journal-title":"Lung Cancer"},{"key":"383_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/annonc\/mdw016","volume":"27","author":"PF Ferrucci","year":"2017","unstructured":"Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2017;27:732\u20138.","journal-title":"Ann Oncol"},{"key":"383_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/sj.bjc.6602702","volume":"93","author":"H Schmidt","year":"2005","unstructured":"Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273\u20138.","journal-title":"Br J Cancer"},{"key":"383_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/COC.0b013e31829b5605","volume":"38","author":"NM Rochet","year":"2015","unstructured":"Rochet NM, Kottschade LA, Grotz TE, Porrata LF, Markovic SN. The prognostic role of the preoperative absolute lymphocyte count and absolute monocyte count in patients with resected advanced melanoma. Am J Clin Oncol. 2015;38:252\u20138.","journal-title":"Am J Clin Oncol"},{"key":"383_CR14","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"383_CR15","doi-asserted-by":"publisher","first-page":"e51862","DOI":"10.1371\/journal.pone.0051862","volume":"7","author":"J1 Budczies","year":"2012","unstructured":"Budczies J1, Klauschen F, Sinn BV, Gy\u0151rffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7:e51862.","journal-title":"PLoS One"},{"key":"383_CR16","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.21873\/anticanres.11221","volume":"36","author":"T Tang","year":"2016","unstructured":"Tang T, Eldabaje R, Yang L. Current status of biological therapies for the treatment of metastatic melanoma. Anticancer Res. 2016;36:3229\u201341.","journal-title":"Anticancer Res"},{"key":"383_CR17","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","volume":"62","author":"AM Di Giacomo","year":"2013","unstructured":"Di Giacomo AM, Calabro L, Danielli R, Fonsatti E, Bertocci E, Pesce I, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg\/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62:1021\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"383_CR18","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/bjc.2015.180","volume":"112","author":"PF Ferrucci","year":"2015","unstructured":"Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer. 2015;112:1904\u201310.","journal-title":"Br J Cancer"},{"key":"383_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/bjd.14155","volume":"174","author":"J Zaragoza","year":"2016","unstructured":"Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, et al. High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. Br J Dermatol. 2016;174:146\u201351.","journal-title":"Br J Dermatol"},{"key":"383_CR20","first-page":"56","volume":"18","author":"MR Cassidy","year":"2017","unstructured":"Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et al. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBio Medicine. 2017;18:56\u201361.","journal-title":"EBio Medicine"},{"key":"383_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","volume":"106","author":"SJ Bagley","year":"2017","unstructured":"Bagley SJ, Kothari S, Aggarwal C, Bauml JM, Alley EW, Evans TL, et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer. 2017;106:1\u20137.","journal-title":"Lung Cancer"},{"issue":"suppl_5","key":"383_CR22","doi-asserted-by":"publisher","first-page":"v295","DOI":"10.1093\/annonc\/mdx371.058","volume":"28","author":"U De Giorgi","year":"2017","unstructured":"De Giorgi U, Procopio G, Guida A, Bearz A, Buti S, Basso U, et al. Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP). Ann Oncol. 2017;28(suppl_5):v295\u2013329.","journal-title":"Ann Oncol"},{"key":"383_CR23","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, et al. Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res. 2016;22:5487\u201396.","journal-title":"Clin Cancer Res"},{"key":"383_CR24","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00262-016-1898-2","volume":"65","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, Vanella V, Grimaldi AM, Lucia F, Palla M, Simeone E, et al. Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. Cancer Immunol Immunother. 2016;65:1395\u2013400.","journal-title":"Cancer Immunol Immunother"},{"key":"383_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.intimp.2016.09.030","volume":"40","author":"J Felix","year":"2016","unstructured":"Felix J, Cassinat B, Porcher R, Schlageter MH, Maubec E, Pages C, et al. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. Int Immunopharmacol. 2016;40:466\u201373.","journal-title":"Int Immunopharmacol"},{"key":"383_CR26","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s00345-012-0942-x","volume":"31","author":"T Hashimoto","year":"2013","unstructured":"Hashimoto T, Ohno Y, Nakashima J, Gondo T, Ohori M, Tachibana M. Clinical significance of preoperative peripheral blood neutrophil count in patients with non-metastatic upper urinary tract carcinoma. World J Urol. 2013;31:953\u20138.","journal-title":"World J Urol"},{"key":"383_CR27","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ejca.2008.06.031","volume":"44","author":"LJ Hawinkels","year":"2008","unstructured":"Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, et al. VEGF release by MMP-9 mediated heparansulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 2008;44:1904\u201313.","journal-title":"Eur J Cancer"},{"key":"383_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13046-015-0256-0","volume":"34","author":"G He","year":"2015","unstructured":"He G, Zhang H, Zhou J, Wang B, Chen Y, Kong Y, et al. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1\/PD-1 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:141.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0383-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0383-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:43:49Z","timestamp":1601041429000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0383-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0383-1","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"P.A. Ascierto has\/had a consultant\/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Amgen, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune. He also received Research funds from Bristol Myers-Squibb, Roche-Genentech, Array.Antonio M. Grimaldi received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis and Roche Genentech, and had consultant\/advisory role for Merck Sharp & Dohme and Novartis.E. Simeone participated to advisory board for Bristol-Myers Squibb and received honoraria from Bristol-Myers Squibb, Novartis and Merck Sharp & Dohme.G. Palmieri has advisory role for Incyte, MSD, Novartis, Pierre-Fabre.All the other authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"74"}}